Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia
1. VENICE-1 observed high response rates (complete or partial remission) in both BCRi-naïve and BCRi-pretreated patients with refractory or relapsed ...
Tag: venetoclax
#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Ibrutinib-Venetoclax Improves Progression-Free Survival in Chronic Lymphocytic Leukemia
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...
The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared ...
Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia
1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared ...